

Reecha Sofat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2510763/publications.pdf>

Version: 2024-02-01

34
papers

3,394
citations

516215

16
h-index

414034

32
g-index

41
all docs

41
docs citations

41
times ranked

7489
citing authors

#	ARTICLE	IF	CITATIONS
1	Free-of-charge medicine schemes in the NHS: A local and regional drug and therapeutic committee's experience. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2571-2580.	1.1	1
2	Pharmacogenomic alerts: Developing guidance for use by healthcare professionals. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3201-3210.	1.1	3
3	Evaluation of antithrombotic use and COVID-19 outcomes in a nationwide atrial fibrillation cohort. <i>Heart</i> , 2022, 108, 923-931.	1.2	12
4	Overprescribing and rational therapeutics: Barriers to change and opportunities to improve. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 34-38.	1.1	8
5	Beyond dexamethasone, emerging immuno-thrombotic therapies for COVID-19. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 845-857.	1.1	6
6	Remdesivir for COVID-19 in Europe: will it provide value for money?. <i>Lancet Respiratory Medicine</i> , 2021, 9, 127-128.	5.2	14
7	Why We Are Losing the War Against COVID-19 on the Data Front and How to Reverse the Situation. <i>Jmirx Med</i> , 2021, 2, e20617.	0.2	8
8	Authors'™ Response to Peer Reviews of "Why We Are Losing the War Against COVID-19 on the Data Front and How to Reverse the Situation". <i>Jmirx Med</i> , 2021, 2, e29421.	0.2	0
9	A novel approach to support implementation of biosimilars within a UK tertiary hospital. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 23-28.	1.1	7
10	Drug and therapeutics committees as guardians of safe and rational medicines use. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 10-12.	1.1	16
11	Association between Angiotensin Blockade and Incidence of Influenza in the United Kingdom. <i>New England Journal of Medicine</i> , 2020, 383, 397-400.	13.9	38
12	Polypharmacy: the whys, the so whats and the what nexts. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2020, 81, 1-7.	0.2	3
13	Are high-cost drug funding mechanisms fit for purpose? A retrospective study of individual funding requests in an NHS tertiary hospital. <i>British Journal of Clinical Pharmacology</i> , 2020, , .	1.1	2
14	<scp><i>RBCK1</i></scp>-related disease: A rare multisystem disorder with polyglucosan storage, auto-inflammation, recurrent infections, skeletal, and cardiac myopathy" Four additional patients and a review of the current literature. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 1002-1013.	1.7	23
15	24-Hour vs. Spot Urinary Sodium and Potassium Measurements in Adult Hypertensive Patients: A Cohort Validation Study. <i>American Journal of Hypertension</i> , 2019, 32, 983-991.	1.0	6
16	A chronological map of 308 physical and mental health conditions from 4 million individuals in the English National Health Service. <i>The Lancet Digital Health</i> , 2019, 1, e63-e77.	5.9	192
17	Bleeding in cardiac patients prescribed antithrombotic drugs: electronic health record phenotyping algorithms, incidence, trends and prognosis. <i>BMC Medicine</i> , 2019, 17, 206.	2.3	12
18	Resistant Hypertension. <i>Hypertension</i> , 2018, 71, 772-780.	1.3	0

#	ARTICLE	IF	CITATIONS
19	Causal Associations of Adiposity and Body Fat Distribution With Coronary Heart Disease, Stroke Subtypes, and Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017, 135, 2373-2388.	1.6	304
20	Association of C-Reactive Protein Genetic Polymorphisms With Late Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2017, 135, 909.	1.4	13
21	Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. <i>BMJ: British Medical Journal</i> , 2017, 359, j5058.	2.4	373
22	Screening strategies for atrial fibrillation: a systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2017, 21, 1-236.	1.3	103
23	Cross-talk between iNKT cells and monocytes triggers an atheroprotective immune response in SLE patients with asymptomatic plaque. <i>Science Immunology</i> , 2016, 1, .	5.6	44
24	Selecting instruments for Mendelian randomization in the wake of genome-wide association studies. <i>International Journal of Epidemiology</i> , 2016, 45, 1600-1616.	0.9	232
25	Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 327-336.	5.5	122
26	Circulating Apolipoprotein E Concentration and Cardiovascular Disease Risk: Meta-analysis of Results from Three Studies. <i>PLoS Medicine</i> , 2016, 13, e1002146.	3.9	35
27	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. <i>Lancet</i> , 2015, 385, 351-361.	6.3	562
28	Distribution and determinants of circulating complement factor H concentration determined by a high-throughput immunonephelometric assay. <i>Journal of Immunological Methods</i> , 2013, 390, 63-73.	0.6	33
29	Complement factor H genetic variant and age-related macular degeneration: effect size, modifiers and relationship to disease subtype. <i>International Journal of Epidemiology</i> , 2012, 41, 250-262.	0.9	79
30	The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. <i>Lancet</i> , 2012, 379, 1214-1224.	6.3	886
31	Could NICE guidance on the choice of blood pressure lowering drugs be simplified?. <i>BMJ</i> , 2012, 344, d8078-d8078.	3.0	8
32	<i>PLA2G7</i> Genotype, Lipoprotein-Associated Phospholipase A ₂ Activity, and Coronary Heart Disease Risk in 10 494 Cases and 15 624 Controls of European Ancestry. <i>Circulation</i> , 2010, 121, 2284-2293.	1.6	111
33	Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With <i>CETP</i> Gene Polymorphisms. <i>Circulation</i> , 2010, 121, 52-62.	1.6	96
34	Genetic variation in complement factor H and risk of coronary heart disease: Eight new studies and a meta-analysis of around 48,000 individuals. <i>Atherosclerosis</i> , 2010, 213, 184-190.	0.4	27